SG11202110449YA - Small molecule degraders of stat3 - Google Patents
Small molecule degraders of stat3Info
- Publication number
- SG11202110449YA SG11202110449YA SG11202110449YA SG11202110449YA SG11202110449YA SG 11202110449Y A SG11202110449Y A SG 11202110449YA SG 11202110449Y A SG11202110449Y A SG 11202110449YA SG 11202110449Y A SG11202110449Y A SG 11202110449YA SG 11202110449Y A SG11202110449Y A SG 11202110449YA
- Authority
- SG
- Singapore
- Prior art keywords
- stat3
- small molecule
- molecule degraders
- degraders
- small
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
- C07F9/3804—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se) not used, see subgroups
- C07F9/3882—Arylalkanephosphonic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962823949P | 2019-03-26 | 2019-03-26 | |
| US201962884995P | 2019-08-09 | 2019-08-09 | |
| PCT/US2020/024892 WO2020198435A1 (en) | 2019-03-26 | 2020-03-26 | Small molecule degraders of stat3 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202110449YA true SG11202110449YA (en) | 2021-10-28 |
Family
ID=70286026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202110449YA SG11202110449YA (en) | 2019-03-26 | 2020-03-26 | Small molecule degraders of stat3 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230083015A1 (en) |
| EP (1) | EP3946619A1 (en) |
| JP (1) | JP2022527298A (en) |
| KR (1) | KR20220009941A (en) |
| CN (1) | CN114269763A (en) |
| AU (1) | AU2020248002A1 (en) |
| CA (1) | CA3134822A1 (en) |
| IL (1) | IL286567A (en) |
| MA (1) | MA55516A (en) |
| MX (1) | MX2021011753A (en) |
| SG (1) | SG11202110449YA (en) |
| WO (1) | WO2020198435A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4121055A4 (en) * | 2020-03-17 | 2024-04-24 | Kymera Therapeutics Inc | Stat degraders and uses thereof |
| CA3226162A1 (en) | 2021-07-09 | 2023-01-12 | Plexium, Inc. | Aryl compounds and pharmaceutical compositions that modulate ikzf2 |
| WO2023133336A1 (en) * | 2022-01-10 | 2023-07-13 | Recludix Pharma, Inc. | Stat modulators and uses thereof |
| CN117126231A (en) * | 2022-05-25 | 2023-11-28 | 杭州和正医药有限公司 | Peptoid STAT protein degradation agent, composition and application thereof |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| JP2001523958A (en) | 1997-03-21 | 2001-11-27 | ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド | CTLA-4 binding peptides for immunotherapy |
| US6808710B1 (en) | 1999-08-23 | 2004-10-26 | Genetics Institute, Inc. | Downmodulating an immune response with multivalent antibodies to PD-1 |
| EP2829609A1 (en) | 1999-08-24 | 2015-01-28 | E. R. Squibb & Sons, L.L.C. | Human CTLA-4 antibodies and their uses |
| FI2206517T3 (en) | 2002-07-03 | 2023-10-19 | Ono Pharmaceutical Co | Immunopotentiating compositions comprising anti-PD-L1 antibodies |
| LT2439273T (en) | 2005-05-09 | 2019-05-10 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| DK2170959T3 (en) | 2007-06-18 | 2014-01-13 | Merck Sharp & Dohme | ANTIBODIES AGAINST HUMAN PROGRAMMED DEATH RECEPTOR PD-1 |
| AR072999A1 (en) | 2008-08-11 | 2010-10-06 | Medarex Inc | HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE |
| NZ591130A (en) | 2008-08-25 | 2012-09-28 | Amplimmune Inc | Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof |
| WO2010077589A2 (en) | 2008-12-08 | 2010-07-08 | The Regents Of The University Of Michigan Office Of Technology Transfer | Stat3 inhibitors and therapeutic methods using the same |
| SI2376535T1 (en) | 2008-12-09 | 2017-07-31 | F. Hoffmann-La Roche Ag | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| JP4965623B2 (en) | 2009-09-30 | 2012-07-04 | インターナショナル・ビジネス・マシーンズ・コーポレーション | Method, system, and program for supporting input of execution parameters of predetermined software to input field |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| WO2013006490A2 (en) | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to tim3 |
| US20130071403A1 (en) | 2011-09-20 | 2013-03-21 | Vical Incorporated | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
| KR101981873B1 (en) | 2011-11-28 | 2019-05-23 | 메르크 파텐트 게엠베하 | Anti-pd-l1 antibodies and uses thereof |
| US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| AR091649A1 (en) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES |
| WO2014022332A1 (en) | 2012-07-31 | 2014-02-06 | The Brigham And Women's Hospital, Inc. | Modulation of the immune response |
| AU2014230741B2 (en) | 2013-03-15 | 2017-04-13 | Glaxosmithkline Intellectual Property Development Limited | Anti-LAG-3 binding proteins |
| NZ718821A (en) | 2013-09-11 | 2022-07-01 | Medimmune Ltd | Anti-b7-h1 antibodies for treating tumors |
| WO2015127548A1 (en) * | 2014-02-28 | 2015-09-03 | The Royal Institution For The Advancement Of Learning / Mcgill University | Tc-ptp inhibitors as apc activators for immunotherapy |
| CN106103484B (en) | 2014-03-14 | 2021-08-20 | 诺华股份有限公司 | Antibody molecules against LAG-3 and uses thereof |
| US11597739B2 (en) * | 2017-08-24 | 2023-03-07 | The Royal Institution For The Advancement Of Learning/Mcgill University | Enhancing CD8+ T cells for adoptive T cell therapy by inhibiting PTPN1 (PTP1B) and PTPN2 (TC-PTP) |
-
2020
- 2020-03-26 SG SG11202110449YA patent/SG11202110449YA/en unknown
- 2020-03-26 WO PCT/US2020/024892 patent/WO2020198435A1/en unknown
- 2020-03-26 JP JP2021557614A patent/JP2022527298A/en active Pending
- 2020-03-26 MX MX2021011753A patent/MX2021011753A/en unknown
- 2020-03-26 MA MA055516A patent/MA55516A/en unknown
- 2020-03-26 EP EP20719095.0A patent/EP3946619A1/en not_active Withdrawn
- 2020-03-26 CN CN202080039100.9A patent/CN114269763A/en active Pending
- 2020-03-26 US US17/442,666 patent/US20230083015A1/en active Pending
- 2020-03-26 KR KR1020217034009A patent/KR20220009941A/en unknown
- 2020-03-26 AU AU2020248002A patent/AU2020248002A1/en not_active Abandoned
- 2020-03-26 CA CA3134822A patent/CA3134822A1/en active Pending
-
2021
- 2021-09-22 IL IL286567A patent/IL286567A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA55516A (en) | 2022-02-09 |
| EP3946619A1 (en) | 2022-02-09 |
| JP2022527298A (en) | 2022-06-01 |
| KR20220009941A (en) | 2022-01-25 |
| CN114269763A (en) | 2022-04-01 |
| WO2020198435A1 (en) | 2020-10-01 |
| MX2021011753A (en) | 2022-01-31 |
| CA3134822A1 (en) | 2020-10-01 |
| IL286567A (en) | 2021-12-01 |
| US20230083015A1 (en) | 2023-03-16 |
| AU2020248002A1 (en) | 2021-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3787747A4 (en) | Small molecule degraders of polybromo-1 (pbrm1) | |
| IL286567A (en) | Small molecule degraders of stat3 | |
| IL275761A (en) | Benzamide compounds | |
| SG11202010347XA (en) | Stat3 inhibitors | |
| EP3766529A4 (en) | Composition for purification of biofluids | |
| EP3723757A4 (en) | Small molecule degraders that recruit dcaft15 | |
| SG11202103282YA (en) | Small molecule mdm2 protein degraders | |
| GB2570922B (en) | Purification of hydrocarbons | |
| GB2587720B (en) | Structural analysis of ionised molecules | |
| IL287876A (en) | Jak inhibitors | |
| EP3857635A4 (en) | Chemical prealkaliation of electrodes | |
| IL252533A0 (en) | Planar transformer components comprising electrophoretically deposited coating | |
| EP3320901A4 (en) | Application of dimethylamino micheliolide | |
| SG11202104554QA (en) | Coating solution | |
| IL267782B (en) | Chemical entities suitable for therapy | |
| IL290381A (en) | Jak inhibitors | |
| IL289266A (en) | Novel molecules | |
| GB2603344B (en) | Cachability of single page applications | |
| ZA202105399B (en) | Use of spiropidion | |
| SG11202105136WA (en) | Application of chidamide | |
| IL291611A (en) | Jak inhibitors | |
| GB201919193D0 (en) | Novel molecules | |
| GB2584687B (en) | Crystallisation of chemical molecules | |
| GB201809911D0 (en) | Use of trpv1 agonists | |
| PL3606515T4 (en) | Stat3 inhibitor formulation |